Consider ENBREL for Patients with Moderate to Severe RA
ENBREL is indicated for reducing signs and symptoms of RA, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.1
Learn more about the efficacy of ENBREL from leading rheumatologists
Treating Moderately Active RA
Take a deeper dive into key RA clinical studies with KOL, Dr. Strand.
Rapid, Sustained Efficacy of ENBREL
Review the rapid and sustained efficacy of ENBREL with KOL, Dr. Fleischmann.
ENBREL demonstrated significant and sustained efficacy
Across clinical studies, ENBREL demonstrated efficacy in patients with moderate to severe RA1-4:
signs and symptoms
See change from baseline in pain, morning stiffness, and CRP.
See reductions in HAQ scores.
See percentage of patients achieving DAS 28 clinical remission.
Inhibited progression of
See changes in mTSS across clinical studies.
The risk of progressive structural damage is high in patients with moderate to severe RA. Structural damage may still be occurring in your RA patients despite clinical improvements with MTX alone. Adding ENBREL to MTX in moderate to severe RA has been shown to be significantly more effective than MTX alone in helping to stop progressive joint damage.
In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.